FGF23 and X-linked hypophosphatemia: In 2018, the European Medicines Agency (EMA) granted conditional marketing authorization to the anti-FGF23 monoclonal antibody burosumab for the treatment of XLH in children aged ≥ 1 year with a growing skeleton and evidence radiography of bone diseases [19].